An Intracerebroventricular Injection to Analyze Murine Cytomegalovirus Distribution in a Neonatal Mouse Brain
JoVE Encyclopedia of Experiments
Neuroscience
0 views • 2:59 min • July 8th, 2025
Loading...
Overview
This article describes a method for injecting murine cytomegalovirus into the lateral ventricle of neonatal mice. The procedure allows for the visualization of the virus using enhanced green fluorescent protein.
Key Study Components
Area of Science
- Neuroscience
- Virology
- Neonatal animal models
Background
- Murine cytomegalovirus can be genetically engineered for research purposes.
- Injection into the lateral ventricle allows for direct access to the cerebrospinal fluid.
- Understanding viral infection in the brain can provide insights into neurodevelopmental processes.
- Fluorescent markers enable visualization of viral spread and infection dynamics.
Purpose of Study
- To establish a protocol for injecting murine cytomegalovirus into neonatal mice.
- To visualize the infection process using enhanced green fluorescent protein.
- To study the interaction between the virus and brain cells.
Methods Used
- Preparation of murine cytomegalovirus suspension.
- Anesthesia of neonatal mice using ice.
- Precise marking and injection technique into the lateral ventricle.
- Monitoring recovery and responsiveness post-injection.
Main Results
- The virus successfully circulates through the cerebrospinal fluid.
- Infection is established in the choroid plexus and surrounding areas.
- Fluorescent visualization confirms the presence of the virus in targeted brain regions.
- The method allows for reproducible results in studying viral infections.
Conclusions
- The injection technique is effective for studying murine cytomegalovirus in neonatal mice.
- Enhanced green fluorescent protein provides a useful tool for visualizing viral dynamics.
- This model can be used to further investigate viral pathogenesis in the central nervous system.
Frequently Asked Questions
What is the significance of using murine cytomegalovirus?
Murine cytomegalovirus serves as a model to study viral infections in the brain and their effects on neurodevelopment.
How does the injection technique ensure accuracy?
The technique involves precise anatomical landmarks and careful insertion to minimize damage and ensure correct placement.
What are the recovery protocols for the injected mice?
Mice are allowed to recover in a warm environment until they regain movement and responsiveness.
Can this method be applied to other viruses?
Yes, the technique can be adapted for other viral studies in neonatal models.
What are the potential applications of this research?
This research can help in understanding viral infections, neurodevelopmental disorders, and potential therapeutic interventions.
Executive Industry Relevance
This method enables precise delivery of viral vectors to the neonatal brain ventricular system, supporting early-stage target validation in neurovirology and CNS disease models. By visualizing viral distribution via fluorescent reporters, it provides mechanistic insights into pathogen-host interactions relevant to antiviral screening and biomarker discovery. The approach supports preclinical de-risking of neurotropic compounds by establishing reproducible infection dynamics in a disease-relevant system.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses regarding viral entry, replication, and spread in developing brain tissue.
- Operational Value: Enables functional validation of CNS targets through observable infection patterns in periventricular zones.
- Predictive Value: Supports portfolio triage by modeling neuroinvasive pathogen behavior in a neonatal disease-relevant system.
Screening & Assay Development
- Assay Readiness: Prepares standardized biological systems for evaluating antiviral compounds that inhibit ventricular CSF-mediated viral dissemination.
- Quantitative Output: Generates measurable fluorescent signals in defined brain regions (choroid plexus, marginal zone, subventricular zone) for dose-response tracking.
- Scalability: Supports platform reuse across viral strains and fluorescent reporters for comparative screening campaigns.
Translational & Preclinical Research
- Disease Relevance: Models congenital CMV infection pathways, aligning with translational biomarker research in neonatal neurodevelopment.
- Preclinical Continuity: Bridges discovery to validation by establishing reproducible CNS infection kinetics for lead optimization.
- Risk-Adjusted Decisions: Informs go/no-go criteria based on viral load distribution and replication efficiency in critical brain compartments.
Pipeline & Workflow Integration
The technique fits within the discovery-to-preclinical continuum, enabling hypothesis testing in early discovery, assay-ready model generation in screening, and mechanistic de-risking in translational research.
- Discovery Biology: Supports pathway clarification by tracking virus-CSF interactions and cellular tropism in ventricular structures.
- Screening: Delivers assay-standardized models with quantifiable fluorescent readouts for compound efficacy assessment.
- Analytics: Provides spatial and temporal infection data enabling comparative analysis of viral mutants or therapeutic interventions.
- Translational Research: Connects to preclinical validation through conserved infection niches in neonatal and developing brain models.
- Enterprise Reuse: Establishes a reusable ventricular delivery platform applicable to neurotropic viruses, gene therapy vectors, and nanoparticle tracers.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in neurotropic infection models through direct ventricular access and fluorescent tracking.
- Operational Value: Ensures reproducibility via standardized coordinates, volume control, and recovery protocols.
- Strategic Value: Improves go/no-go decisions by predicting CNS penetration and target engagement early in discovery.
- Portfolio Impact: Enables risk-adjusted prioritization of neuroactive compounds based on ventricular delivery efficiency and infection fidelity.
Implementation Considerations
- Requires expertise in neonatal animal handling, microsurgery, and fluorescent microscopy.
- Dependent on precision instrumentation including calibrated microsyringes and stereotaxic markers.
- Necessitates cross-team standardization of anesthesia depth, injection volume, and post-procedure monitoring.
- Adaptation across models must account for ventricular size variations and developmental stage-specific CSF dynamics.
- Practical limitations include technical variability in needle placement and potential ventricular backflow if needle retention time is insufficient.
Biopharma FAQs
Why does ventricular delivery method matter for target validation?
Direct intracerebroventricular injection ensures precise access to cerebrospinal fluid, enabling consistent viral distribution to periventricular brain regions. This reproducibility supports reliable assessment of viral tropism and host-cell interactions critical for validating neurotropic targets in early discovery.
How does isolating the ventricular space as an independent variable improve discovery pipeline fidelity?
By delivering virus directly into the lateral ventricle, the method isolates CSF-mediated spread as a key variable, minimizing confounding vascular or parenchymal delivery effects. This enables clearer attribution of observed infection patterns to ventricular-specific mechanisms, improving target hypothesis testing.
What do quantitative fluorescence measurements in choroid plexus and subventricular zone enable?
Fluorescent signal intensity in defined brain regions provides quantifiable readouts of viral replication and spread, allowing dose-dependent analysis of antiviral compounds or genetic mutants. These measurements support objective comparison across experimental conditions in screening workflows.
Why are replication and recovery timing requirements important for cross-functional collaboration?
Standardized recovery periods (5–10 minutes) and needle retention (10–20 seconds) ensure consistent physiological states across subjects, reducing variability in viral uptake and early replication. This consistency enables reliable data sharing between discovery, screening, and translational teams.
What statistical analysis capabilities are needed before implementing this method in screening campaigns?
Implementation requires the ability to quantify regional fluorescence intensity, compare infection rates across groups, and assess variance in ventricular delivery accuracy. These capabilities support meaningful statistical evaluation of compound effects on viral CNS distribution and replication efficiency.
10:58
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Related Videos
0 Views
06:04
Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Related Videos
0 Views
07:57
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Related Videos
0 Views
07:42
Mosaic Analysis of Gene Function in Postnatal Mouse Brain Development by Using Virus-based Cre Recombination
Related Videos
0 Views
05:55
Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
Related Videos
0 Views
02:21
Generation of a Murine Model with a Central Nervous System Infection
Related Videos
0 Views
05:53
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Related Videos
0 Views
10:15
Intracerebroventricular Viral Injection of the Neonatal Mouse Brain for Persistent and Widespread Neuronal Transduction
Related Videos
0 Views
05:17
Intravenous Injections in Neonatal Mice
Related Videos
0 Views
05:51
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Related Videos
0 Views
Last updated: 18 July 2026